NEOSCAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Neoscan, and what generic alternatives are available?
Neoscan is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in NEOSCAN is gallium citrate ga-67. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the gallium citrate ga-67 profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NEOSCAN?
- What are the global sales for NEOSCAN?
- What is Average Wholesale Price for NEOSCAN?
Summary for NEOSCAN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 7 |
Clinical Trials: | 1 |
Patent Applications: | 54 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NEOSCAN at DailyMed |
Recent Clinical Trials for NEOSCAN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
United States Department of Defense | Phase 2 |
Eli Lilly and Company | Phase 2 |
Memorial Sloan Kettering Cancer Center | Phase 2 |
US Patents and Regulatory Information for NEOSCAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ge Healthcare | NEOSCAN | gallium citrate ga-67 | INJECTABLE;INJECTION | 017655-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |